Actim Partus 1ngeni

Actim® Partus 1ngeni

Quantitative confidence for prediction of preterm delivery

The next generation Actim® Partus 1ngeni not only detects or rules out the risk of preterm or imminent delivery, but also provides precise data about the severity of the risk, giving you the confidence in choosing early and crucial treatment strategies.

Automated confidence in Actim testing

Actim Partus 1ngeni quantitatively measures phosphorylated insulin-like growth factor binding protein-1 (phIGFBP-1) concentration in cervical secretions. The higher the concentration, the higher the risk.

Actim Partus 1ngeni test results are quantified and interpreted, displayed and stored automatically by using the Actim® 1ngeni instrument. This digital point-of-care system is logical and intuitive to use, and provides quantitative test results in just 5 minutes.

Clinical performance

phIGFBP-1
concentration (ng/mL)
Delivery
≤ 7 days
Delivery
≤ 14 days
Delivery
before 30 weeks
Delivery
before 34 weeks
Delivery
before 37 weeks
≤2
2.1-9.95.3*1.50.51.41.6*
10.0-49.95.8*2.15.8*3.3**2.4***
50.0-249.97.7*4.2*11.5**4.1**2.4***
≥25013.6**11.1***20.3***8.7***3.9***
Relative risk of preterm delivery categorized according to phIGFBP-1 concentration in Actim Partus 1ngeni test
(relative risk compared to phIGFBP-1 ≤ 2 ng/mL z-statistics significance: *p < 0.05, **p < 0.01, ***p < 0.001).

Actim Partus 1ngeni test is performed
using the Actim 1ngeni instrument

  • Fast and easy testing with traceable documentation
    Automated testing and digital data storage save time and ensure assay consistency. The results are reported in just 5 minutes.
  • Clear quantification and interpretation of test results
    The phIGFBP-1 concentration is reported as a numerical value with the description of estimated risk for preterm or imminent labor:
    < 10 ng/mL, low risk of preterm delivery
    ≥ 10 ng/mL, elevated risk of preterm delivery
  • Early prediction of preterm or imminent delivery
    Actim Partus 1ngeni test is taken from cervical secretions in women with intact fetal membranes and can be performed from gestational week 22 onwards. Accurate detection of an elevated risk is crucial for choosing the right treatment early